Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Category: Patent Prosecution
-
By James DeGiulio — AstraZeneca Settles Entocort Patent Suit with Teva, Stipulates with Mylan AstraZeneca has settled its infringement claims against Teva over its Crohn's disease treatment Entocort, striking a deal that grants Teva an exclusive license to market a generic oral budesonide capsule on Feb. 15, 2012. The companies will seek approval for…
-
"Biotech/Pharma" Top 47" By Donald Zuhn — The Intellectual Property Owners Association (IPO) released its 27th annual list of the top 300 organizations receiving U.S. patents. Patent Docs Readers may recall that the U.S. Patent & Trademark Office stopped releasing its annual list of top patent recipients in 2006 in order to "discourag[e] any…
-
By Donald Zuhn — Earlier this year, we released our annual list of top biotech/pharma stories (see "Top Stories of 2009: #4 to #1"). At the top of our list, we placed the biotech/pharma industry's attempts to recover from the Great Recession. Back in February of 2009, we noted that almost a third of…
-
By Donald Zuhn — Last month, the Association of University Technology Managers (AUTM) released its U.S. licensing survey for FY2008. According to a GenomeWeb Daily News report, a majority of the academic and research institutions that answered the survey indicated that they filed more patent applications and were involved in more start-ups during the…
-
Implications for Patent Protection for Avonex® Anti-Multiple Sclerosis Drug By Kevin E. Noonan — There is a tendency to blame the process when an undesired outcome occurs. That is happening in the wake of regulatory filings with the Securities and Exchange Commission regarding U.S. Patent 7,588,755 (the '755 patent), issued on September 15, 2009,…
-
By Donald Zuhn — On Monday, the American Bar Association (ABA) Standing Committee on Ethics and Professional Responsibility released a statement regarding a new ethics opinion (Formal Opinion 08-451), which concludes that U.S. lawyers can outsource legal and nonlegal work provided that they adhere to ethics rules regarding competence, supervision, protection of confidential…
-
By Donald Zuhn — Last week, a panel of biopharma attorneys participated in a breakout session at the BIO International Convention to discuss the impact of the Supreme Court’s decision in KSR Int’l Co. v. Teleflex Inc. on biopharma patent prosecution and litigation. Participating in the panel, entitled "Biopharma IP Strategies in the…
-
By Donald Zuhn — Yesterday, Gilead Sciences, Inc. announced that the U.S. Patent and Trademark Office had issued a Notice of Intent to Issue an Ex Parte Reexamination Certificate for U.S. Patent No. 5,922,695. The ‘695 patent became the second of Gilead’s four Viread® (tenofovir disoproxil fumarate) patents to survive reexamination. Last month,…
-
By Donald Zuhn — Last month, Larkspur, California-based biotech Jivan Biologics, Inc. announced that the U.S. Patent and Trademark Office had granted its request for an ex parte reexamination of U.S. Patent No. 6,881,571, which is owned by ExonHit Therapeutics S.A. The ‘571 patent is directed to devices for identifying differentially spliced gene…
-
By Kevin E. Noonan — The so-called Coalition for Patent Fairness has been one of the principal voices lobbying Congress for the now-becalmed Senate "patent reform bill (S. 1145) and the House version of the bill (H.R. 1938), passed last September. The Coalition is comprised of "high technology" companies like Apple, Cisco, Intel,…
Patent Docs 